Iranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
Why APLM Stock surged +4.16% Today — RQD Quant Desk Flash
Apollomics Inc. (Class A) (APLM) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is APLM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Apollomics Inc. (Class A) (NASDAQ: APLM) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $20.80 (+4.16% 1D, market cap $60.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, APLM ranks #166 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does APLM compare to XBIT and VRCA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APLM carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, XBIT (XBiotech Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $59.1M) and VRCA (Verrica Pharmaceuticals Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $58.8M). Among the 5-stock peer group, APLM leads on earnings multiple (N/A) while XBIT leads on capital efficiency (-35.0% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for APLM?
▼
For Apollomics Inc. (Class A) (APLM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #166 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 56% of 52W Range • RSI-14 at 42.5 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±10.8% realized swing band)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
⚔️ Adversarial Opposing Case: Why the APLM Bull Thesis Could Fail
Even with a 62/100 (C) score, APLM faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($23.31) or 200D SMA ($18.95) invalidates the momentum regime and cuts Target Base ($21.17) toward Bear Floor ($16.51).
Why APLM Stock surged +4.16% Today — RQD Quant Desk Flash
Apollomics Inc. (Class A) (APLM) surged +4.16% to $20.80, trading at 56% of its 52-week range ($11.3 – $28.29). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 56% of its 52-week range ($11.3 – $28.29) with RSI-14 at 42.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.8% around $20.80 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $1.7M annual free cash flow.
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
Saudi civil defence sounds all-clear after alerts in southern cities Reuters
World's energy supply buffers have been eroded, ADNOC CEO says Reuters
Gold rises on softer oil; markets parse Fed signals Reuters
China's Xi says Middle East should not become battleground for great power rivalry Reuters
Reliance earnings, lower oil prices power India's Sensex to near two-month high Reuters
Dollar pulls back ahead of US midterms; bitcoin stabilises after crypto heist Reuters
Scheduled RQD Strong Buys & Whale Accumulation Briefing (APLM Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
APLM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on APLM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for APLM. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APLM)
1. Head-to-Head Health Care Peer Comparison (APLM vs. XBIT, VRCA, INCR, RFL)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Apollomics Inc. (Class A) (APLM) ranks #166 by composite RQD confidence (62/100, grade C) and #724 by equity capitalization ($60.2M). Within this direct 5-issuer industry benchmark cohort, APLM leads on earnings valuation at N/A trailing P/E, while XBIT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APLM currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| APLM
ACTIVE
Apollomics Inc. (Class A) | C | 62/100 | — | — | — | +4.16% | $60.2M | Benchmark Subject |
| XBIT XBiotech Inc. | D- | 37/100 | — | — | -35.0% | -2.51% | $59.1M | /xbit-vs-aplm → |
| VRCA Verrica Pharmaceuticals Inc. | D | 44/100 | — | — | -35.0% | -1.72% | $58.8M | /vrca-vs-aplm → |
| INCR Intercure Ltd. | D | 48/100 | — | — | — | -7.83% | $61.8M | /incr-vs-aplm → |
| RFL Rafael Holdings Inc. (Class B) | E | 16/100 | — | — | -35.0% | -7.44% | $58.2M | /rfl-vs-aplm → |
2. APLM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTApollomics Inc. (Class A) (APLM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $60.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. APLM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs APLM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Apollomics Inc. (Class A) (NASDAQ: APLM) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $20.80 (+4.16% 1D, market cap $60.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, APLM ranks #166 in composite RQD confidence.
How does APLM compare to XBIT and VRCA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APLM carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, XBIT (XBiotech Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $59.1M) and VRCA (Verrica Pharmaceuticals Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $58.8M). Among the 5-stock peer group, APLM leads on earnings multiple (N/A) while XBIT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for APLM?
For Apollomics Inc. (Class A) (APLM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #166 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is APLM trading relative to its 50-day, 200-day, and 52-week technical levels?
APLM last traded at $20.80 (+4.16% on volume of 63,258 shares), positioning the stock -10.77% below its 50-day simple moving average ($23.31) and +9.76% above its 200-day simple moving average ($18.95). Across its 52-week range of $11.30 to $28.29, APLM sits at the 55.9% percentile with a 14-day RSI of 42.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($18.55 to $23.05).
APLM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is APLM stock moving today?
Why APLM Stock surged +4.16% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.